Urothelial Cancer and Bladder Cancer
Tyra Biosciences Inc. focuses on clinical research in advanced urothelial carcinoma and non-muscle invasive bladder cancer (NMIBC), with an emphasis on tumors linked to FGFR3 alterations. Its studies address disease settings where targeted treatment strategies are being explored in genitourinary oncology.
- Advanced urothelial carcinoma
- Non-muscle invasive bladder cancer (NMIBC)
- FGFR3 gene alterations
The sponsor’s clinical programme includes both localized bladder cancer and more advanced urinary tract malignancies, reflecting interest in disease control across distinct stages of urothelial disease.
FGFR-Targeted Oncology
The research portfolio is centred on fibroblast growth factor receptor 3 (FGFR3)-driven cancers, including solid tumors with activating molecular changes. This places the sponsor within the field of precision oncology, with attention to biomarker-defined patient groups.
- FGFR3-altered solid tumors
- Molecularly selected cancer populations
- Targeted oncology
Clinical activity extends beyond bladder cancer to other solid tumors carrying the same actionable alteration, indicating a therapeutic interest in shared oncogenic pathways.
Solid Tumor Therapeutics
Tyra Biosciences Inc. also supports research in advanced solid tumors, where the goal is to assess treatment activity in cancer types that remain difficult to manage. The sponsor’s work spans heterogeneous tumor settings unified by a common molecular target.
- Advanced solid tumors
- Tumor expansion cohorts
- Antitumor activity
This area of interest connects oncology drug development with the evaluation of targeted approaches in multiple malignancies, particularly where FGFR3 activation is present.
